Differences in health status between long-term and short-term benzodiazepine users

British Journal of General Practice

Volumn 52, Issue 483, 2002, Pages 805-808

  Zandstra, S M ^a   Furer, J W ^a   Van De Lisdonk, E H ^a   Bor, J H J ^a   Zitman, F G ^a   Van Weel, C ^a  

^a NONE   (Netherlands)

Author keywords

Benzodiazepines; Health status; Prescription failure

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CENTRAL STIMULANT AGENT; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADULT; AGED; ANAMNESIS; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG USE; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; HYPERTENSION; INTERVIEW; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDICAL SPECIALIST; MENTAL DISEASE; MENTAL HEALTH; MORBIDITY; NETHERLANDS; PATIENT CARE; PATIENT REFERRAL; PHYSICAL PARAMETERS; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SHORT COURSE THERAPY; SKIN DISEASE;

ADULT; AGED; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FAMILY PRACTICE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0036790305     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Committee on the Safety of Medicines (CSM). Benzodiazepines, dependence and withdrawal symptoms. Curr Probl 1988; 21: 1-2.
2. Salzman C. The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. [Editorial.] Am J Psychiatry 1991; 148: 151-152.
3. Gabe J. Promoting benzodiazepine withdrawal. Addiction 1994; 89: 1497-1504.
4. Balter MB, Manheimer DI, Mellinger GD, Uhlenhuth EH. A cross-national comparison of anti-anxiety/sedative drug use. Curr Med Res Opin 1984; 8 (Suppl 4): 5S-20S.
5. Barbui C, Gregis M. Zappa M. A cross-sectional audit of benzodiazepine use among general practice patients. Acta Psychiatr Scand 1998; 97:153-156.
6. Magrini N, Vaccheri A, Parma, et al. Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. [See comments.] Eur J Clin Pharmacol 1996; 50: 19-25.
7. Mellinger GD, Balter MB, Uhlenhuth EH. Anti-anxiety agents: duration of use and characteristics of users in the USA. Curr Med Res Opin 1984; 8 (Suppl 4): 21S-36S.
8. Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 1984; 251: 375-379.
9. Ohayon MM, Caulet M. Priest RG, Guilleminault C. Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 1998; 51: 273-283.
10. Rodrigo EK, King MB, Williams P. Health of long-term benzodiazepine users. BMJ 1988; 296: 603-606.
11. Salinsky JV, Dore CJ. Characteristics of long-term benzodiazepine users in general practice. J R Coll Gen Pract 1987; 37: 202-204.
12. Van Hulten R, Leufkens H, Bakker A. Usage patterns of benzodiazepines in a Dutch community: a 10-year follow-up. Pharm World Sci 1998; 20: 78-82.
13. Wells K, Kamberg C, Brook R, et al. Health status, sociodemographic factors, and the use of prescribed psychotropic drugs. Med Care 1985; 23: 1295-1306.
14. Ashton H, Golding JF. Tranquillisers: prevalence, predictors and possible consequences. Data from a large United Kingdom survey. Br J Addict 1989; 84: 541-546.
15. Blijenberg-Ruis B, Garretsen HFL, Schuurman JH, Verdonk ALT. The use of sleep medication and tranquilizers. Tijdschrift voor Sociale Gezondheidszorg 1986; 64: 491-497.
16. Catalan J, Gath DH, Bond A, et al. General practice patients on long-term psychotropic drugs. A controlled investigation. Br J Psychiatr 1988; 152: 399-405.
17. Gene BJ, Blay PC, Soler VM. Risk factors in the use of benzodiazepines. Fam Pract 1988; 5: 283-288.
18. Lagro-Janssen ALM, Liberton ILW. Profiles of regular consumers of benzodiazepines in a general practice. Nederlands Tijdschrift voor Geneeskunde 1993; 137: 1969-1973.
19. Mellinger GD, Balter MB, Manheimer DI, et al. Psychic distress, life crisis, and use of psychotherapeutic medications: national household survey data. Arch Gen Psychiatr 1978; 35: 1045-1052.
20. Simpson RJ, Power KG, Wallace LA, et al. Controlled comparison of the characteristics of long-term benzodiazepine users in general practice. [See comments.] Br J Gen Pract 1990; 40: 22-26.
21. Uhlenhuth EH, Balter MB, Lipman RS. Minor tranquilizers: clinical correlates of use in an urban population. Arch Gen Psychiatr 1978; 35: 650-655.
22. Vissers FHJA, Jongbloet AH, Knottnerus JA. Benzodiazepinen: de gebruiker en zijn huisarts. [Benzodiazepines, the user and his general practitioner.] Huisarts en Wetenschap 1998; 41: 323-327.
23. Isacson D. Long-term benzodiazepine use: factors of importance and the development of individual use patterns overtime - a 13-year follow-up in a Swedish community. Soc Sci Med 1997;44:1871-1880.
24. Zandstra SM, Furer JW, Lisdonk van de EH et al. Different study criteria affect the prevalence of benzodiazepine use. Soc Psychiatr Psychiatr Epidemiol 2002; 37: 139-144.
25. Van der Waals FW. Sex differences among recipients of benzodiazepines in Dutch General Practice. Amsterdam: Academic Medical Centre, University of Amsterdam, Department of Women's Health. [Thesis.] 1995.
26. Konig-Zahn C, Furer JW, Tax B, et al. Regioproject Nijmegen 2: Psychiatrische morbiditeit in de regio. [The Nijmegen Health Area Project No 2: psychiatric morbidity in NHA2.] Nijmegen: UMC Nijmegen, Department of Social Medicine, General Practice and Psychiatry, 1999.
27. WHO Collaborating Centre for Drugs. Statistics Methodology Guidelines ATC Classification and DDD Assignment. Oslo: WHO/NCM, 1996.
28. van den Berg J, van den Bos GAM. Het (meten van het) voorkomen van chronische aandoeningen 1974-1987. [The (measurement of the) presence of chronic disorders.) Maandblad Gezondheid (CBS) 1989; 4-21.
29. Ware JE, Snow KK, Kosinski M., Gandeli B. SF-36 Health Survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993.
30. Van der Zee K, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36: een handleiding. RU Groningen: Noordelijk Centrum voor Gezondheidsvraagstukken, 1993.
31. Goldberg DP, Williams P. A user's guide to the General Health Questionnaire. Windsor: NFER-Nelson, 1988.
32. Koeter MWJ, Ormel J. General Health Questionnaire Nederlandse Bewerking (Manual). Lisse: Swets and Zeitlinger, 1991.
33. Jorm AF, Duncan-Jones P. Neurotic symptoms and subjective well-being in a community sample: different sides of the same coin? Psychol. Med. 1990; 20: 647-654.
34. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley Interscience, 1989; 171-175.
35. Geijer RMM, Thiadens HA, Smeele IJM, et al. NHG-standard COPD en astma bij volwassenen: diagnostiek. [Guidelines of the Dutch College of General Practitioners on asthma in adults - diagnosis.] Huisarts en Wetenschap 2001; 44: 107-117.
36. Geijer RMM, Van Schayck CP, Van Weel C, et al. NHG-standard COPD: behandeling. [Guidelines of the Dutch College of General Practitioners on COPD.] Huisarts en Wetenschap 2001; 44: 207-219.
37. Rutten GEHM, Verhoeven S, Heine RJ, et al. NHG-standard diabetes mellitus type 2. Huisarts en Wetenschap 1999; 42: 67-84.
38. Walma EP, Grundmeijer HGLM, Thomas S, et al. (eds) NHG-Standaarden voor de huisarts I. Maarssen: Elsevier/Bunge, 1999: 187-205.
39. Tata PR, Rollings J, Collins M, et al. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol Med 1994; 24: 203-213.
40. Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995; 155: 1801-1807.
41. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatr 1990; 47: 899-907.
42. Power KG, Jerrom DW, Simpson RJ, Mitchell M. Controlled study of withdrawal symptoms and rebound anxiety after six-week course of diazepam for generalised anxiety. BMJ 1985; 290: 1246-1248.
43. Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 1999; 9 (SUPPL. 6): 399S-405S.